Diabetic Peripheral Neuropathy Market Size & Share, Epidemiology and Forecast till 2030

DelveInsight’s ‘Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Diabetic Peripheral Neuropathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Diabetic Peripheral Neuropathy from 2017 to 2030 segmented by seven major markets. 

Diabetic peripheral neuropathy (DPN) also known distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease. 

The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others. 

The clinical manifestations of DPN include painful diabetic neuropathy (pDPN) that is often accompanied by burning pain, aching, shooting, stabbing and paresthesia or allodynia often present in arms, hands, legs, and feet. DPN without painful symptoms is referred to as nonpainful diabetic neuropathy (non-pDPN). Due to the presence of pain, pDPN patients are expected to get diagnosed and expected to incur higher health care costs compared to the general population and non-pDPN.

Diabetic Peripheral Neuropathy - Disease Understanding

Diabetic Peripheral Neuropathy Overview

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies. It is common prevalent complication in neurological damage of Type 1 and Type 2 diabetes, main risk factors contributing to DPN are smoking, obesity, hyperlipidemia, duration of diabetes, large total exposure to hyperglycemia, advanced age, elevated lipid levels, elevated blood pressure, kidney disease, cigarette smoking, overweight, increased height, and others.

The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others. 

Diabetic Peripheral Neuropathy Epidemiology

The Diabetic peripheral neuropathy epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

DelveInsight’s estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017. Among 7MM, United States has the prevalent population of Diabetic Peripheral Neuropathy with about 12,522,483 cases in 2017. Among EU-5 countries, Germany has the highest prevalent cases with 3,904,730 cases, followed by Italy with 1,636,426 cases in 2017. However, Spain has the least number of diagnosed prevalent cases. All these cases are expected to increase by 2030.

Diabetic Peripheral Neuropathy Drug Chapters

This segment of the Diabetic Peripheral Neuropathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.

Diabetic Peripheral Neuropathy Market Outlook

The Diabetic Peripheral Neuropathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

[According to DelveInsight, the market of Diabetic Peripheral Neuropathy in 7MM was found to be approximately USD 2,275.52 Million in 2017.]

Diabetic Peripheral Neuropathy market size in the United States was maximum of the total market in 2017, followed by the EU5 and Japan respectively. 

Diabetic Peripheral Neuropathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Various pharmaceutical companies are developing therapies such as VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others which are expected to enter the market by 2030 as effective therapies. 

Frequently asked questions:

What is Diabetic Peripheral Neuropathy (DPN)?

Diabetic Peripheral Neuropathy is defined as the symptoms of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. The disease is also known as Distal symmetric polyneuropathy (DSPN).

What was the Diabetic Peripheral Neuropathy market size in the 7MM in 2017?

Diabetic Peripheral Neuropathy Market Size was USD 2,275.52 Million in the 7MM in 2017. 

Which geography accounted for the largest Diabetic Peripheral Neuropathy market size?

The United States accounted for the highest market size with USD 1,309.98 Million in 2017 among 7MM.

Which companies are developing drugs for Diabetic Peripheral Neuropathy?

Helixmith, Aptinyx, WinSanTor, Inc, Regenacy Pharmacuticals, Ichnos Science, Novaremed, Grünenthal GmbH, Glenmark Pharmaceuticals, AstraZeneca, Angelini.

How is epidemiology segmented for Diabetic Peripheral Neuropathy?

Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM.

Click here to access the full report or visit the link below: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market